At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 30 enrolled
Drug / intervention
Spironolactonedrug
Likely dose
Spironolactone 25 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Spironolactone to Prevent or Delay Calcineurin Inhibitor (CNI) Toxicity in Liver Transplant Recipients
In Brief
A Phase 4 clinical trial evaluating Spironolactone for Transplant, Liver. Completed, enrolled 30 participants across 1 site.
Detailed Summary
To study spironolactone to prevent calcineurin inhibitor (CNI) kidney injury.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTransplant, Liver
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartDec 2014
First PostedAug 2016
Primary CompletionJan 2018
TodayJul 2026
First PostedAug 30, 2016
Enrollment StartDec 1, 2014
Primary CompletionJan 1, 2018
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 9.8 years ago
Interventions
Spironolactonedrug
spironolactone 25 mg up to 50 mg